Inovio Pharmaceuticals Inc. closed 88.27% short of its 52-week high of $14.75, which the company reached on April 1st.

Shares of Inovio Pharmaceuticals Inc. INO slid 3.72% to $1.81 Tuesday, on what proved to be an all-around positive trading ...

Good afternoon, ladies and gentlemen, and welcome to the INOVIO Pharmaceuticals fourth quarter 2024 financial results ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107.

Inovio Pharmaceuticals (NASDAQ:INO – Free Report) had its target price lowered by Royal Bank of Canada from $6.00 to $5.00 in a research report sent to investors on Wednesday,Benzinga reports. The ...

Shares of Inovio Pharmaceuticals stock opened at $1.92 on Friday. The firm has a market cap of $50.11 million, a price-to-earnings ratio of -0.91 and a beta of 0.92. The business has a 50-day ...

In a report released yesterday, Gregory Renza from RBC Capital maintained a Hold rating on Inovio Pharmaceuticals (INO – Research Report), with ...

Inovio Pharmaceuticals Inc (NASDAQ:INO) has resolved the manufacturing issue with the single-use array component of the Selectra device, which is crucial for their BLA submission for INO 3,107. The ...

Inovio Pharmaceuticals reported a net loss of $19.4 million for the fourth quarter of 2024, equating to $0.65 per share. The company’s full-year net loss amounted to $107.3 million, or $3.95 per ...